Stay updated on Idasanutlin Combo Therapy in AML Clinical Trial

Sign up to get notified when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Idasanutlin Combo Therapy in AML Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:58:00.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a modification in the study record details related to the safety and efficacy evaluation of Idasanutlin in combination with Cytarabine and Daunorubicin for patients with Acute Myeloid Leukemia (AML). This change may be significant for individuals monitoring medical and healthcare-related publications and documentation.
    Difference
    0.1%
    Check dated 2024-06-06T14:43:02.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as ECOG performance status, hepatic and renal function, and contraceptive measures for both men and women. Previously, this section only indicated that no information was provided.
    Difference
    34%
    Check dated 2024-05-22T21:24:20.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:36:24.000Z thumbnail image

Stay in the know with updates to Idasanutlin Combo Therapy in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.